Cellagility Biomed has the capability to deliver a highly optimized safety service, externally benchmarked with audited quality assurance. A guarantee of our Safe-iPSC potential for future clinical use.
Cellagility Biomed owns process backed by IP under development in culture medium and cryogenic storage capable of increasing post thaw viability.
The processes designed and implemented by Cellagility Biomed offer an opportunity for a considerable reduction in cost for our clients.
SAFE-iPSC-5™ Test Platform
Cellagility Biomed is soon going to launch its test platform that has multiple test capabilities and will offer 3 tier precision for your cell line screening needs.